Randomized Comparison Of Imipenem/Cilastatin and Ceftazidime in The Empiric Therapy of Severe Abdominal Infections a Multicenter Study
作者:
BrozeB.,
De MeesJ.,
DroissartR.,
NolensV.P.,
StaudtJ.P.,
VerstraetenM.E.,
De LameP.A.,
期刊:
Acta Clinica Belgica
(Taylor Available online 1987)
卷期:
Volume 42,
issue 6
页码: 431-436
ISSN:1784-3286
年代: 1987
DOI:10.1080/22953337.1987.11719261
出版商: Taylor&Francis
数据来源: Taylor
摘要:
SummaryFifty-six patients with severe intra-abdominal infection have been included in a controlled randomized open study. Imipenem/cilastatin was administered to 28 patients. The remaining 28 patients received ceftazidime, including 7 patients who received a combination of ceftazidime with metronidazole. The difference in cure rates did not reach statistical difference, although 3 failures were reported in the ceftazidime group and none in the imipenem/cilastatin group.Based on 100 pretreatment antibiograms, far more organisms were susceptible to imipencm (99) than to ceftazidime (80) (p<0.001). The Presence of a pathogen resistant to therapy in the follow-up culture was observed more frequently in the ceftazidime group (p<0.05).Tolerance and safety profile were good in both groups.It is concluded that imipenem/cilastatin is an efficient empiric monotherapy in severe intra-abdominal infections.
点击下载:
PDF (4216KB)
返 回